TargetBeta
ATP4A
ATPase H+/K+ transporting subunit alpha · also ATP6A · ATPase H+/K+ transporting
6 programs in company-led studies act on ATP4A, from 5 companies: 0 in phase 3, 6 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tegoprazanrule | HK inno.N | phase 4 | 487 running | ATP4B | ChEMBL |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 295 running | ATP4B | ChEMBL |
| Omeprazolerule | AstraZeneca | phase 4 | 562 running | ATP4B | ChEMBL |
| vonoprazanrule | Takeda | phase 4 | 482 running | ATP4B | ChEMBL |
| Esomeprazolerule | AstraZeneca | phase 4 | 1291 running | ATP4B | ChEMBL |
| Rabeprazolerule | Eisai | phase 4 | 661 running | ATP4B | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Gastroesophageal Reflux, 6 programs
- Heartburn, 4 programs
- Stomach Ulcer, 4 programs
- Esophagitis, 3 programs
- Duodenal Ulcer, 2 programs
- Esophagitis, Peptic, 2 programs
- Gastrointestinal Diseases, 2 programs
- Non-Erosive Reflux Disease, 2 programs
- Peptic Ulcer, 2 programs
- HIV Infections, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Rabeprazole · Eisai · phase 4 · NCT07608666
- Jan 31, 2027tegoprazan · HK inno.N · phase 4 · NCT07853248
- Aug 2027Omeprazole · AstraZeneca · phase 4 · NCT07918859
- Oct 20, 2027vonoprazan · Takeda · phase 4 · NCT07752407
- Dec 2027fexuprazan · Daewoong Pharmaceutical · phase 4 · NCT07533266
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.